** Drug developer KalVista Pharmaceuticals KALV.O decline about 7.4% to $12 premarket
** FDA extends review of KALV's experimental drug, sebetralstat, citing heavy workload and limited resources
** Health Secretary Robert F. Kennedy Jr. directed the FDA to fire 3,500 employees as part of a massive restructuring of U.S. health agencies in March
** TD Cowen says that the delay does not appears to do with the drug's safety or efficacy
** "Although disappointing, we expect little impact on the launch," says brokerage, adding that they expect significant demand from patients who suffer from a type of swelling disorder called hereditary angioedema
** Co says FDA plans to deliver a decision within four weeks
** KALV up 53% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。